U.S. pharmaceutical company Gilead Sciences announces positive results from the phase 2 SWIFT study of the oral drug candidate emvistegrast for the treatment of moderate to severe ulcerative colitis. The study achieved its primary endpoint after 12 weeks.
Clinical response was achieved in 66 percent of patients who received 200 milligrams of emvistegrast daily, compared with 37 percent in the placebo group. Clinical remission was achieved in 31 and 8 percent, respectively. Several secondary endpoints also showed statistically significant improvements based on nominal p-values.
The treatment was generally well tolerated. Serious adverse events were reported in 2 percent of patients who received emvistegrast, but were not considered drug-related.
Gilead plans to initiate a phase 3 study of emvistegrast as monotherapy in 2027. The SWIFT study continues with additional follow-up.